Stage (next event)
Catalyst Info & Data Links
TITLE: REVASCOR® (Rexlemestrocel) in Advanced Heart Failure - Phase 3 Data
ClinicalTrial.gov (NCT02032004): Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. (DREAM HF-1)
WHAT IS THE CATALYST EVENT?
Phase 3 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
10-28-2020 Quarterly Activity Report
posters and publications
CHF prevalence is expected to grow 46% by 2030, affecting more than 8 million Americans (Learn more HERE).
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post